Toshiaki Shirakata Selected Research

Toshiaki Shirakata Research Topics

24	Neoplasms (Cancer) 01/2022 - 09/2004
5	Leukemia 01/2012 - 09/2004
4	Wilms Tumor (Wilm's Tumor) 01/2022 - 01/2007
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 03/2010 - 09/2004
3	Hematologic Neoplasms (Hematological Malignancy) 05/2009 - 05/2007
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 04/2006
2	Hypersensitivity (Allergy) 03/2013 - 09/2009
2	Residual Neoplasm 10/2010 - 09/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2010 - 09/2004
2	Erythema 05/2008 - 09/2004
2	Leukopenia 06/2007 - 09/2004
2	Lung Neoplasms (Lung Cancer) 01/2007 - 09/2004
1	Ascites 01/2022
1	Disease Progression 01/2022
1	Inflammation (Inflammations) 01/2022
1	Melanoma (Melanoma, Malignant) 08/2019
1	Salivary Gland Neoplasms (Salivary Gland Cancer) 03/2012
1	Carcinoma (Carcinomatosis) 03/2012
1	Neoplasm Metastasis (Metastasis) 03/2012
1	Pleomorphic Adenoma 03/2012
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2009
1	Colonic Neoplasms (Colon Cancer) 05/2009
1	Stomach Neoplasms (Stomach Cancer) 05/2009
1	Colorectal Neoplasms (Colorectal Cancer) 05/2009
1	Carcinogenesis 05/2009
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 05/2009
1	Glioblastoma (Glioblastoma Multiforme) 05/2008
1	Multiple Myeloma 12/2007
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 06/2007
1	Pancytopenia 05/2007
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2007
1	Fibrosarcoma 04/2006

18	Peptides (Polypeptides)IBA 01/2022 - 09/2004
11	AntigensIBA 01/2022 - 09/2004
7	Protein Subunit VaccinesIBA 01/2022 - 09/2004
7	WT1 ProteinsIBA 03/2012 - 09/2004
6	Proteins (Proteins, Gene)FDA Link 03/2010 - 10/2004
4	VaccinesIBA 01/2022 - 09/2004
4	HLA-A Antigens (HLA-A)IBA 11/2008 - 01/2007
3	Immunoglobulin G (IgG)IBA 01/2022 - 05/2007
3	Cancer VaccinesIBA 01/2022 - 04/2006
2	EpitopesIBA 01/2012 - 01/2008
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 08/2011 - 03/2010
2	LigandsIBA 03/2008 - 12/2007
2	Protein Isoforms (Isoforms)IBA 03/2008 - 04/2006
2	Messenger RNA (mRNA)IBA 06/2007 - 10/2004
1	HLA-A*24:02 antigenIBA 01/2022
1	Serum AlbuminIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Cell Wall SkeletonIBA 08/2019
1	Monatide (IMS 3015)IBA 03/2012
1	Histocompatibility Antigens Class IIBA 01/2012
1	InterferonsIBA 01/2012
1	Aurora Kinase AIBA 01/2012
1	Neoplasm Antigens (Tumor Antigens)IBA 08/2011
1	Imatinib Mesylate (Gleevec)FDA Link 10/2010
1	multiple myeloma M-proteinsIBA 09/2009
1	Peptide Elongation Factors (Elongation Factor)IBA 05/2009
1	Phosphotransferases (Kinase)IBA 05/2009
1	Peptide Elongation Factor 2 (EF-2)IBA 05/2009
1	Small Interfering RNA (siRNA)IBA 05/2009
1	Etoposide (VP 16)FDA LinkGeneric 03/2008
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2008
1	HLA-A*02:01 antigenIBA 01/2008
1	AntibodiesIBA 05/2007
1	Immunoglobulin IsotypesIBA 05/2007
1	Immunoglobulin M (IgM)IBA 05/2007
1	Gemcitabine FDA Link 05/2007
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 10/2004
1	Tumor Biomarkers (Tumor Markers)IBA 09/2004